Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Review of Updated Guidelines and Evidence for Antithrombotic Therapy in Acute Ischemic Stroke

급성 허혈성 뇌졸중에서 항혈전제 치료의 최신 가이드라인 개정과 근거에 대한 고찰

  • Soo-Heui Paik (College of Pharmacy, Sunchon National University)
  • 백수희 (국립순천대학교 약학과)
  • Received : 2024.05.21
  • Accepted : 2024.06.13
  • Published : 2024.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: There was an important revision of the Korean Clinical Practice Guideline for Stroke (KCPGS) for antithrombotic therapy in patients with acute ischemic stroke in 2022. This review is to provide an updated information in this revision. Methods: The revision history by year after the first announcement was examined for each topic, focusing on antithrombotic therapy during acute phase which was revised in 2022. We compared before and after the revision, and investigated the clinical outcomes presented as evidence. It was also compared with the current U.S. guidelines. Results: The major changes about antiplatelet therapy are a clause stating that dual antiplatelet therapy with clopidogrel and aspirin initiated within 24 hours from the stroke onset and maintained for up to 21-30 days is recommended as an acute treatment, as well as the clause that antithrombotic therapy may be initiated within 24 hours after intravenous thrombolytics and that the use of glycoprotein IIb/IIIa receptor antagonists can be considered in highly selected patients as rescue therapy taking into account of benefit and risk. The change to the use of anticoagulants is that it may be reasonable to start oral anticoagulant between 4 and 14 days after stroke onset for patients with acute ischemic stroke and atrial fibrillation. Conclusions: It will be helpful in improving health outcomes for clinical pharmacists to be aware of the latest information for antithrombotic therapy and to actively use it in pharmaceutical care of stroke patients.

Keywords

References

  1. Clinical Research Center for Stroke and Korean Stroke Society. Korean clinical practice guideline for stroke. Available from https://www.stroke.or.kr/guidelines/. Accessed February 10, 2024.
  2. Health Insurance Review and Assessment Service. 2022 cerebrovascular disease treatment status. Available from https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020041000100&brdScnBlt-No=4&brdBltNo=10980. Accessed February 18, 2024.
  3. Korean Stroke Registry. KSR annual report 2023. Available from http://www.strokedb.or.kr/report/file_download.asp?f_type=report&-filename=KSR_Annual_Report_2023_Kor_20230406.pdf. Accessed February 18, 2024.
  4. Cho HJ, Kang TH. Pharmacological secondary prevention of ischemic stroke. Brain & NeuroRehabilitation 2014;7(2):10.
  5. Park HK, Ko SB, Jung KH, et al. 2022 update of the korean clinical practice guidelines for stroke: Antithrombotic therapy for patients with acute ischemic stroke or transient ischemic attack. J Stroke 2022;24(1):166-75.
  6. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2019;50(12):e344-e418.
  7. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the american heart association/american stroke association. Stroke 2021;52(7):e364-e467.
  8. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (chinese acute stroke trial) collaborative group. Lancet 1997;349(9066):1641-9.
  9. The international stroke trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International stroke trial collaborative group. Lancet 1997;349(9065):1569-81.
  10. Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the cast and ist collaborative groups. Stroke 2000;31(6):1240-9.
  11. Sandercock PA, Counsell C, Tseng MC, Cecconi E. Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2014;2014(3):Cd000029.
  12. Jeong H, Kim BJ, Yang MH, Han M, Bae H, Lee S. Stroke outcomes with use of antithrombotics within 24 hours after recanalization treatment. Neurology 2016;87(10):7.
  13. Wells DA, Davis LK, Saeed O, et al. Safety of early antiplatelet administration in patients with acute ischemic stroke treated with alteplase (SEAPT-24). J Stroke Cerebrovasc Dis 2022;31(12):106868.
  14. Adams HP, Jr., Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial: Abciximab in emergency treatment of stroke trial (AbESTT-II). Stroke 2008;39(1):87-99.
  15. Zhang S, Hao Y, Tian X, et al. Safety of intra-arterial tirofiban administration in ischemic stroke patients after unsuccessful mechanical thrombectomy. J Vasc Interv Radiol 2019;30(2):141-7 e1.
  16. Kim YW, Sohn SI, Yoo J, et al. Local tirofiban infusion for remnant stenosis in large vessel occlusion: Tirofiban assist study. BMC Neurol 2020;20(1):284.
  17. Baek BH, Yoon W, Lee YY, Kim SK, Kim JT, Park MS. Intravenous tirofiban infusion after angioplasty and stenting in intracranial atherosclerotic stenosis-related stroke. Stroke 2021;52(5):1601-8.
  18. Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke. Cochrane Database Syst Rev 2014(3):Cd005208.
  19. Siebler M, Hennerici MG, Schneider D, et al. Safety of tirofiban in acute ischemic stroke: The SaTIS trial. Stroke 2011;42(9):2388-92.
  20. Pancioli AM, Broderick J, Brott T, et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: The CLEAR stroke trial. Stroke 2008;39(12):3268-76.
  21. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369(1):11-9.
  22. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018;379(3):215-25.
  23. Pan Y, Elm JJ, Li H, et al. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: A pooled analysis of clopidogrel in high-risk patients with acute non-disabling cerebrovascular events (CHANCE) and platelet-oriented inhibition in new tia and minor ischemic stroke (POINT) trials. JAMA Neurol 2019;76(12):1466-73.
  24. Bath PM, Woodhouse LJ, Appleton JP, et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): A randomised, open-label, phase 3 superiority trial. Lancet 2018;391(10123):850-9.
  25. Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016;375(1):35-43.
  26. Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020;383(3):207-17.
  27. Lee YS, Bae HJ, Kang DW, et al. Cilostazol in acute ischemic stroke treatment (CAIST trial): A randomized double-blind non-inferiority trial. Cerebrovasc Dis 2011;32(1):65-71.
  28. Kwon SU, Cho Y-J, Koo J-S, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis. Stroke 2005;36(4):782-6.
  29. Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: The multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005;36(4):782-6.
  30. Kwon SU, Hong KS, Kang DW, et al. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke 2011;42(10):2883-90.
  31. Uchiyama S, Sakai N, Toi S, et al. Final results of cilostazol-aspirin therapy against recurrent stroke with intracranial artery stenosis (CATHARSIS). Cerebrovasc Dis Extra 2015;5(1):1-13.
  32. Gotoh F, Tohgi H, Hirai S, et al. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000;9(4):147-57.
  33. Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010;9(10):959-68.
  34. Clinical Research Center for Stroke and Korean Stroke Society. Korean clinical practice guidelines for stroke (summary). Available from https://www.stroke.or.kr/guidelines/. Accessed February 10, 2024.
  35. Huang Y, Cheng Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: A randomised, double-blind, pilot study. Lancet Neurol 2008;7(6):494-9.
  36. Clinical Research Center for Stroke and Korean Stroke Society. Korean clinical practice guideline for stroke: Antithrombotic therapy of cardioembolic stroke or TIA; 3.3.3.1. Atrial fibrillation. Available from https://www.stroke.or.kr/guidelines/view.php?sid=100. Accessed February 10, 2024.
  37. Paciaroni M, Agnelli G, Falocci N, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: Effect of anticoagulation and its timing: The RAF study. Stroke 2015;46(8):2175-82.
  38. Wilson D, Ambler G, Banerjee G, et al. Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: Multicentre cohort study. J Neurol Neurosurg Psychiatry 2019;90(3):320-5.
  39. Arihiro S, Todo K, Koga M, et al. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The samurai-nonvalvular atrial fibrillation (NVAF) study. Int J Stroke 2016;11(5):565-74.
  40. Mizoguchi T, Tanaka K, Toyoda K, et al. Early initiation of direct oral anticoagulants after onset of stroke and short- and long-term outcomes of patients with nonvalvular atrial fibrillation. Stroke 2020;51(3):883-91.
  41. Lee SH, Hong KS, Lee JS, et al. Prediction of hemorrhagic transformation in patients with mild atrial fibrillation-associated stroke treated with early anticoagulation: Post hoc analysis of the Triple AXEL trial. Clin Neurol Neurosurg 2018;174:156-62.
  42. Hong KS, Choi YJ, Kwon SU, Triple AI. Rationale and design of Triple AXEL: Trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation. Int J Stroke 2015;10(1):128-33.
  43. Hong KS, Kwon SU, Lee SH, et al. Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation-related mild ischemic stroke: A randomized clinical trial. JAMA Neurol 2017;74(10):1206-15.
  44. Gioia LC, Kate M, Sivakumar L, et al. Early rivaroxaban use after cardioembolic stroke may not result in hemorrhagic transformation: A prospective magnetic resonance imaging study. Stroke 2016;47(7):1917-9.
  45. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39(16):1330-93.
  46. Fischer U, Trelle S, Branca M, et al. Early versus late initiation of direct oral anticoagulants in post-ischaemic stroke patients with atrial fibrillation (ELAN): Protocol for an international, multicentre, randomised-controlled, two-arm, open, assessor-blinded trial. Eur Stroke J 2022;7(4):487-95.
  47. Best JG, Arram L, Ahmed N, et al. Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trial. Int J Stroke 2022;17(5):583-9.
  48. Oldgren J, Asberg S, Hijazi Z, et al. Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (TIMING): A registry-based randomized controlled noninferiority study. Circulation 2022;146(14):1056-66.
  49. Correction to: Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (TIMING): A registry-based randomized controlled noninferiority study. Circulation 2022;146(19):e279.
  50. King BT, Lawrence PD, Milling TJ, Warach SJ. Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation (START): Methodology of a pragmatic, response-adaptive, prospective randomized clinical trial. Int J Stroke 2019;14(9):977-82.
  51. Clinical Research Center for Stroke and Korean Stroke Society. Korean clinical practice guideline for stroke: 3.2. Antithrombotic therapy for noncardioembolic stroke or transient ischemic attack. Available from https://www.stroke.or.kr/guidelines/index.php. Accessed February 10, 2024.
  52. Clinical Research Center for Stroke and Korean Stroke Society. Korean clinical practice guideline for stroke: 3.4.1. Extracranial carotid artery stenosis (revised in 2011). Available from https://www.stroke. or.kr/guidelines/view.php?sid=76. Accessed February 10, 2024.
  53. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: The clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation 2005;111(17):2233-40.
  54. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093-104.
  55. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91.
  56. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92.
  57. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51.